BioPharm Drill Flashcards
BIOAVAILABILITY
A. RELATIONSHIP BETWEEN THE PHYSICAL & CHEMICAL PROPERTIES OF A DRUGAND ITS SYSTEMIC ABSORPTION
B. MEASUREMENT OF THE RATE & AMOUNT OF THERAPEUTICALLY ACTIVE DRUG THAT REACHES THE SYSTEMIC CIRCULATION
C. MOVEMENT OF THE DRUG INTO BODY TISSUES OVER TIME D. DISSOLUTION OF THE DRUG IN THE GIT
D. AMOUNT OF DRUG DESTROYED BY THE LIVER BEFORE SYSTEMIC ABSORPTION FROM THE GIT OCCURS
B. MEASUREMENT OF THE RATE & AMOUNT OF THERAPEUTICALLY ACTIVE DRUG THAT REACHES THE SYSTEMIC CIRCULATION
THE ROUTE OF DRUG ADMINISTRATION THAT GIVES THE MOST RAPID ONSET OF THE PHARMACOLOGIC EFFECT IS:
A. IM INJ
B. IV INJ
C. INTRADERMAL INJ
D. PER-ORAL ADMINISTRATION
IV INJ
AFTER PER-ORAL ADMINISTRATION, DRUGS GENERALLY ABSORBED BEST FROM THE
A. BUCCAL CAVITY
B. STOMACH
C. DUODENUM
D. ILEUM
E. RECTUM
DUODENUM
THE CHARACTERISTICS OF AN ACTIVE
TRANSPORT PROCESS INCLUDES ALL OF THE FOLLOWING EXCEPT:
A. ACTIVE TRANSPORT MOVES DRUG
MOLECULES AGAINST A CONCENTRATION GRADIENT
B. ACTIVE TRANSPORT FOLLOWS FICK’S LAW OF DIFFUSION
C. ACTIVE TRANSPORT IS A CARRIERMEDIATED TRANSPORT SYSTEM
D. ACTIVE TRANSPORT REQUIRES ENERGY
E. ACTIVE TRANSPORT OF DRUG MOLECULES MAYBE SATURATED AT HIGH CONCENTRATIONS
ACTIVE TRANSPORT FOLLOWS FICK’S LAW OF DIFFUSION
PASSAGE OF MOLECULES WILL TEND TO MOVE FROM THE HIGHER CONCENTRATIONS SIDE TO THE LOWER CONCENTRATIONS SIDE
A. ACTIVE TRANSPORT
B. BIOAVAILABILITY
C. BIOPHARMACEUTICS
D. SIMPLE DIFFUSION
SIMPLE DIFFUSION
WHICH EQUATION DESCRIBES THE RATE OF DRUG DISSOLUTION FROM A TABLET?
A. FICK’S LAW
B. HENDERSON-HASSELBALCH
C. LAW OF MASS ACTION
D. MICHAELIS-MENTEN EQUATION
E. NOYES-WHITNEY EQUATION
NOYES-WHITNEY EQUATION
WHICH CONDITION USUALLY INCREASES THE RATE OF DRUG DISSOLUTION FROM A TABLET?
USE OF IONIZED OR SALT FORM OF DRUG
DOSE DUMPING IS A PROBLEM IN THE FORMULATION OF A COMPRESSED TABLET?
MODIFIED RELEASE DRUG PRODUCT
THE RATE LIMITING STEP IN THE BIOAVAILABILITY OF A LIPID SOLUBLE DRUG FORMULATION AS AN IMMEDIATE RELEASE COMPRESSED TABLET IS THE RATE OF:
A. DISINTEGRATION OF THE TABLET & RELEASE OF THE DRUG
B. DISSOLUTION OF THE DRUG
C. TRANSPORT OF THE DRUG MOLECULES
D. ACROSS THE INTESTINAL MUCOSAL CELLS
E. BLOOD FLOW TO THE GIT
DISSOLUTION OF THE DRUG
THE EXTENT OF IONIZATION OF A WEAK ELECTROLYTE DRUG DEPENDS ON THE?
A. PH OF THE MEDIA AND PKA OF THE DRUG
B. OIL TO WATER PARTITION COEFFICIENT OF THE DRUG
C. PARTICLE SIZE & SURFACE AREA OF THEDRUG
D. NOYES-WHITNEY EQUATION FOR THE DRUG
E. POLYMORPHIC FORM OF THE DRUG
PH OF THE MEDIA AND PKA OF THE DRUG
THE RATE OF DRUG BIOAVAILABILITY IS MOST RAPID WHEN THE DRUG IS FORMULATED AS A
A. CONTROLLED-RELEASE PRODUCT
B. HARD GELATINE CAPSULE
C. COMPRESSED TABLET
D. SOLUTION
E. SUSPENSION
SOLUTION
CREATININE CLEARANCE IS USED AS
MEASUREMENT OF
GFR
THE EVIDENCE THAT A DRUG IS STORED IN TISSUES
A. AN INCREASE IN PLASMA PROTEIN BINDING
B. A LARGE APPARENT VOLUME OF DISTRIBUTION
C. DECREASE IN THE RATE OF FORMATION OF METABOLITES
D. DECREASE IN THE AMOUNT OF FREE DRUG EXCRETED IN THE URINE
A LARGE APPARENT VOLUME
OF DISTRIBUTION
THE INTENSITY OF THE PHARMACOLOGIC ACTION OF A DRUG IS MOST DEPENDENT ON
CONCENTRATION OF THE DRUG AT THE
SITE OF ACTION
THE LOADING DOSE OF A DRUG IS USUALLY BASED ON THE
APPARENT VOLUME OF THE DISTRIBUTION
RENAL CLEARANCE OF INULIN IS USED AS MEASUREMENT OF
A. EFFECTIVE RENAL BLOOD FLOW
B. RATE OF RENAL DRUG EXCRETION
C. GFR
D. ACTIVE RENAL
E. INTRINSIC
GFR
ALL OF THE FOLLOWING STATEMENTS ABOUT PROTEIN BINDING ARE TRUE EXCEPT:
A. DISPLACEMENT OF A DRUG FORM PLASMA PROTEIN BINDING SITES RESULT IN A TRANSIENT INCREASE IN VD.
B. DISPLACEMENT OF A DRUG FROM PLASMA PROTEIN BINDING SITES MALES MORE FREE DRUG AVAILABLE FOR GLOMERULAR FILTRATION
C. DISPLACEMENT OF THE POTENT DRUG THAT IS NORMALLY BOUND GREATER THAN 95% MAY CAUSE TOXICITY
D. DRUG HIGHLY BOUND TO PLASMA PROTEIN HAVE A GREATER VD COMPARED WITH DRUGS THAT ARE HIGHLY BOUND TO TISSUE
DRUG HIGHLY BOUND TO PLASMA
PROTEIN HAVE A GREATER VD COMPARED WITH DRUGS THAT ARE HIGHLY BOUND TO TISSUE
THE ONSET TIME FOR A DRUG GIVEN ORALLY IS THE TIME FOR THE DRUG TO:
A. REACH THE PEAK PLASMA DRUG CONCENTRATION.
B. REACH THE MEC
C. REACH THE MTC
D. BEGIN TO BE ELIMINATED FROM THE BODY
E. BEGIN TO BE ABSORBED FROM THE SMALL INTESTINE.
REACH THE PEAK PLASMA DRUG
CONCENTRATION.
THE INITIAL DISTRIBUTION OF A DRUG INTO TISSUE IS DETERMINED CHIEFLY BY THE;
A. RATE OF BLOOD FLOW TO TISSUE
B. GFR
C. STOMACH EMPTYING TIME
D. AFFINITY OF THE DRUG FOR TISSUE
E. PLASMA PROTEIN BINDING OF THE DRUG
RATE OF BLOOD FLOW TO TISSUE
THE INTEGRAL OF DRUG LEVEL OVER TIME FROM ZERO TO INFINITY IS.
A. BIOLOGIC HALF. LIFE
B. AUC
C. BIOAVAILABILITY
D. BIOPHARMACEUTICS
AUC
WHICH TISSUE HAS THE GREATEST CAPACITY TO BIOTRANSFORM DRUGS?
A. BRAIN
B. KIDNEY
C. LIVER
D. LUNG
E. SKIN
LIVER
TO DETERMINE THE ABSOLUTE BIOAVAILABILITY OF A DRUG GIVEN AS AN ORAL EXTENDED RELEASE TABLET, THE BIOAVAILABILITY OF THE DRUG MUST BE COMPARED TO THE BIOAVAILABILITY OF THE DRUG FROM;
A. AN IMMEDIATE RELEASE ORAL TABLET CONTAINING THE SAME AMOUNT OF ACTIVE INGREDIENT
B. AN ORAL SOLUTION OF THE DRUG IN THE SAME DOSE
C. A PARENTERAL SOLUTION OF THE DRUG GIVEN BY INTRAVENOUS BOLUS OR IV INFUSION
D. A REFERENCE (BRAND) EXTENDED
RELEASE TABLET THAT IS A PHARMACEUTICAL EQUIVALENT
A PARENTERAL SOLUTION OF THE DRUG GIVEN BY INTRAVENOUS BOLUS OR IV INFUSION
THE FIRST STEP WHICH DETERMINES THE ONSET OF ACTION, RATE OF ABSORPTION & AVAILABILITY IS;
A. LIBERATION
B. DISTRIBUTION
C. EXCRETION
D. ABSORPTION
LIBERATION
THE RANGE OF DOSES AT WHICH A MEDICATION IS EFFECTIVE WITHOUT UNACCEPTABLE ADVERSE EVENTS.
A. THERAPEUTIC EFFECT
B. THERAPEUTIC INDEX
C. THERAPEUTIC WINDOW
D. NOTA
THERAPEUTIC INDEX
WHEN A SUBSTANCE IS HALF-IONIZED AT A CERTAIN PH, ITS PKA IS
A. GREATER THAN PH
B. LESS THAN PH
C. EQUAL TO PH
D. NEGLIGIBLE AS COMPARED TO PH
EQUAL TO PH
THE NOYES-WHITNEY EQUATION DETERMINES:
A. PARTICLE SIZE MEASUREMENT
B. ACTUAL DRUG SOLUBILITY
C. DISSOLUTION CONSTANT
D. DISSOLUTION RATE
DISSOLUTION RATE
IT REFERS TO THE NET TRANSFER OF A DRUG CIRCULATING FLUIDS OF THE BODY TO VARIOUS TISSUES AND ORGANS.
A. ABSORPTION
B. DISTRIBUTION
C. METABOLISM
D. EXCRETION
DISTRIBUTION
THE TERM USED TO DESCRIBE THE ACHIEVEMENT OF SUSTAINED DRUG CONCENTRATION BY SIMPLY INCREASING THE DOSE SIZE OR BY ACCIDENTAL FAST RELEASE OF DRUG FROM A SUSTAINED RELEASE DOSAGE FROM
A. DOSE CURVE
B. ACCUMULATION
C. DOSE DUMPING
D. DOSE DEPENDENCY
DOSE DUMPING
THIS REFERS TO THE TIME IN HOURS NECESSARY TO REDUCE THE DRUG CONCENTRATION IN THE BLOOD, PLASMA OR SERUM TO ONE-HALF AFTER EQUILIBRIUM IS REACHED
A. HALF-LIFE
B. CLEARANCE
C. ELIMINATION
D. GET
E. HEPATIC CLEARANCE
HALF-LIFE
DRUGS EMPTIED VIA BILE INTO THE SMALL INTESTINE CAN BE REABSORBED FROM INTESTINAL LUMEN INTO THE SYSTEMIC
CIRCULATION IS THE PHENOMENON OF
A. ENTEROHEPATIC RECIRCULATION
B. BILIARY RECYCLING
C. A & B
D. NOTA
A & B
NO QUESTION
A DRUG WHICH POSSESSES AFFINITY & INTRINSIC ACTIVITY:
A. AGONIST
B. ANTAGONIST
C. TOXIN
D. NOTA
AGONIST
A DRUG HAS HIGH SOLUBILITY BUT LOW PERMEABILITY MAY BE CLASSIFIED BASED ON BCS AS:
A. CLASS 1
B. CLASS 2
C. CLASS 3
D. CLASS 4
CLASS 3
THIS IS AN INDICATION OF THE LIPID
SOLUBILITY OF A DRUG AND ITS LIKELIHOOD OF BEING TRANSPORTED ACROSS MEMBRANES:
A. POLYMORPHISM
B. PERMEABILITY
C. PH
D. PARTITION COEFFICIENT
PARTITION COEFFICIENT
DRUGS THAT ARE USUALLY RELEASED MUCH MORE SLOWLY FROM FAT BECAUSE
A. FAT HAS RELATIVELY LIMITED BLOOD SUPPLY
B. DRUGS ARE FAT BOUND THAN PLASMA BOUND
C. FAT DRUGS BOUND TO ITSELF MORE
D. AOTA
FAT HAS RELATIVELY LIMITED BLOOD
SUPPLY
TO ESTABLISH BIOEQUIVALENCE, THE CALCULATED CONFIDENCE INTERVAL SHOULD FALL WITHIN THE PRESCRIBED LIMIT OF:
A. 50-100%
B. 90-110%
C. 80-125%
D. 95-100%
80-125%
CONDITION IN WHICH THE RATE OF DRUG LEAVING THE BODY IS EQUAL TO DRUG
A. DOUBLE-PEAK
B. STEADY STATE
C. FLIP FLOP
D. FIRST-PASS EFFECT
STEADY STATE
DRUG ENTERING THE BODY DOES NOT INSTANTLY DISTRIBUTE BETWEEN THE BLOOD & THOSE OTHER BODY FLUIDS OR TISSUES WHICH IT EVENTUALLY REACHES
A. OPEN-ONE
B. OPEN-TWO COMPARTMENT
C. MULTI-MIL
D. CENTRAL COMPARTMENT
OPEN-TWO COMPARTMENT
RATE CONSTANTS IN PHARMACOKINETICS ARE USUALLY
A. ZERO ORDER
B. FIRST ORDER
C. SECOND ORDER
D. THIRD ORDER
FIRST ORDER
REFERS TO THE USE OF DRUGS OTHER THAN FOOD FOR THE PREVENTION, DIAGNOSIS, TREATMENT, OF A MEDICAL CONDITION AS WELL AS ITS SIGN AND SYMPTOMS
A. PHARMACOTHERAPY
B. PHARMACOVIGILANCE
C. PHARMACOLOGICAL THERAPY
D. A&C
E. B&C
PHARMACOTHERAPY
THE LARGER THE AMOUNT OF TOTAL BODY FLUID AND THE VERY SMALL AMOUNT OF FAT TISSUE IN INFANT MAKE IT LIKELY THAT THE VOLUME OF DISTRIBUTION OF HYDROPHILIC COMPOUNDS IS ___ AND THAT LIPOPHILIC ONES ARE ___
A. INCREASED, DECREASED
B. INCREASED, INCREASED
C. DECREASED, INCREASED
D. DECREASED,DECREASED
INCREASED, DECREASED
DRUG BINDING TO PROTEIN CAN BE CONSIDERED AS A:
A. REVERSIBLE PROCESS
B. IRREVERSIBLE PROCESS
C. LINEAR
D. NON-LINEAR
REVERSIBLE PROCESS
FREE DRUG CONCENTRATION ______ OF PLASMA BINDING, BUT IS _____ ON TISSUE BINDING.
A. INDEPENDENT, DEPENDENT
B. DEPENDENT, INDEPENDENT
C. DEPENDENT, DISSOCIATIVE
D. DISSOCIATIVE, INDEPENDENT
E. AOTA
INDEPENDENT, DEPENDENT
IT IS A HYPOTHETICAL STRUCTURE WHICH CAN BE USED TO
CHARACTERIZED WITH REPRODUCIBILITY THE BEHAVIOUR AND THE FATE OF DRUG IN BIOLOGICAL SYSTEMS
A. CONCEPTS
B. CONSTRUCTS
C. COMPARTMENTS
D. LOCATION
E. MODELS
CONSTRUCTS
ASIANS ARE AT THE GREATEST RISK OF ALL ETHNIC GROUPS FOR GENETIC POLYMORPHISM IN WHICH OF THE FOLLOWING CYTOCHROME P450 ISOENZYMES?
A. CYP 2D6
B. CYP 142
C. CYP 3A4
D. CYP 2C19
CYP 2D6
IN IV INFUSION IT IS ESSENTIAL TO ADMINISTER THE DOSE TO STEADY STATE, LOADING DOSE AND PRIMARY DOSE.
A. LOADING DOSE
B. MAINTENANCE DOSE
C. TITTERED DOSE
D. PRINTING DOSE
E. A AND D
A AND D
MOST COMMONLY USED FORMULA FOR CREATININE CLEARANCE.
A. HENDERSON-HASSELBALCH
B. NOYES WHITNEY
C. COCKROFT & GAULT
D. JELIFIE EQUATION
COCKROFT & GAULT
THIS REFERS TO THE ANATOMICAL LOCATION OF THE RECEPTORS FOR A DRUG:
A. ENZYMES
B. PROTOENZYMES
C. BIOPHASE
D. MICROSOMES
BIOPHASE
UNIT FOR CLEARANCE
A. VOLUME/TIME
B. DRUG/VOLUME
C. CONCENTRATION/TIME
D. CONCENTRATION x TIME
VOLUME/TIME
A PK WHICH A DRUG ENTERS A COMPARTMENT, DISTRIBUTES BETWEEN A CENTRAL & PERIPHERAL COMPARTMENT AND IS ELIMINATED FROM THE SYSTEMIC CIRCULATION.
A. HALF-LIFE
B. VOLUME OF DISTRIBUTION
C. RATE CONSTANT
D. AUC
E. CMA
RATE CONSTANT
